A patient with meningeal melanocytoma and a GNAQ mutation (patient 29) was treated with the MEK inhibitor trametinib (level of evidence stage m1c) with SD in MRI after 3 months of treatment [61]. The gene discussed is MAP2K7; the disease is Meningeal Melanocytoma.